We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Editorial Comment on Prostate cancer and liquid biopsies: Clinical applications and challenges.
- Authors
Goto, Yusuke
- Abstract
Liquid biopsies are a promising tool for the detection and monitoring of prostate cancer (PCa) in patients. In Japan, two comprehensive genomic profiling (CGP) tests for circulating tumor DNA (ctDNA) are covered by insurance, Foundation One liquid CDx® and Guardant 360 CDx®. These tests provide comprehensive genome analysis with next-generation sequencing, with Foundation One liquid CDx® being approved as a companion diagnostic test for BRCA1/2 mutation. The article discusses the potential clinical implications, challenges, and future directions of liquid biopsy in PCa, highlighting the suitability of ctDNA tests for advanced cases and the usefulness of extracellular vesicles (EVs) for early detection and monitoring. The standardized method for sampling and analysis of EVs remains a challenge, but if solved, EVs could provide valuable information on RNA in PCa. Another CGP test using tissue, GenMineTOP® Cancer Genome Profiling System, has also been approved in Japan, allowing for the analysis of RNA and DNA paired with normal tissue. The article concludes by emphasizing the potential of these diagnostic procedures in advancing genome medicine for PCa.
- Subjects
EDITORIAL writing; CLINICAL medicine; PROSTATE cancer; CIRCULATING tumor DNA; LIQUIDS; COMPANION diagnostics
- Publication
International Journal of Urology, 2024, Vol 31, Issue 6, p626
- ISSN
0919-8172
- Publication type
Article
- DOI
10.1111/iju.15456